284 related articles for article (PubMed ID: 8687151)
21. [The mistletoe myth--claims, reality and provable perspectives].
Gabius HJ; André S; Kaltner H; Siebert HC; von der Lieth CW; Gabius S
Z Arztl Fortbild (Jena); 1996 Apr; 90(2):103-10. PubMed ID: 8686332
[TBL] [Abstract][Full Text] [Related]
22. Mistletoe or not mistletoe is still the question.
Kiene H; Büschel G; Hornebar M
Forsch Komplementarmed Klass Naturheilkd; 2001 Oct; 8(5):309-12. PubMed ID: 11760713
[No Abstract] [Full Text] [Related]
23. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
[TBL] [Abstract][Full Text] [Related]
24. Cellular immunomodulation and safety of standardized aqueous mistletoe extract PS76A2 in tumor patients treated for 48 weeks.
Dohmen W; Breier M; Mengs U
Anticancer Res; 2004; 24(2C):1231-7. PubMed ID: 15154652
[TBL] [Abstract][Full Text] [Related]
25. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use".
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Forsch Komplementarmed Klass Naturheilkd; 2004 Aug; 11 Suppl 1():23-9. PubMed ID: 15353899
[TBL] [Abstract][Full Text] [Related]
26. Hypoxic abdominal stop-flow perfusion in the treatment of advanced pancreatic cancer: a phase II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Caterino GP; Di Giuro G; Amicucci G
Eur J Surg Oncol; 2007 Feb; 33(1):72-8. PubMed ID: 17166688
[TBL] [Abstract][Full Text] [Related]
27. Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma.
Furuse J; Kinoshita T; Kawashima M; Ishii H; Nagase M; Konishi M; Nakagohri T; Inoue K; Ogino T; Ikeda H; Maru Y; Yoshino M
Cancer; 2003 Mar; 97(5):1346-52. PubMed ID: 12599244
[TBL] [Abstract][Full Text] [Related]
28. Induction of antibodies to viscotoxins A1, A2, A3, and B in tumour patients during therapy with an aqueous mistletoe extract.
Klein R; Classen K; Fischer S; Errenst M; Scheffler A; Stein GM; Scheer R; von Laue HB
Eur J Med Res; 2002 Aug; 7(8):359-67. PubMed ID: 12204844
[TBL] [Abstract][Full Text] [Related]
29. [Mistletoe therapy. An alternative cancer treatment].
Ernst E
MMW Fortschr Med; 2000 Nov; 142(45):52-3. PubMed ID: 11107826
[No Abstract] [Full Text] [Related]
30. Mistletoe (viscum album) lectins as cytokine inducers and immunoadjuvant in tumor therapy. A review.
Bocci V
J Biol Regul Homeost Agents; 1993; 7(1):1-6. PubMed ID: 8346712
[TBL] [Abstract][Full Text] [Related]
31. Cryosurgery with combination of (125)iodine seed implantation for the treatment of locally advanced pancreatic cancer.
Xu KC; Niu LZ; Hu YZ; He WB; He YS; Zuo JS
J Dig Dis; 2008 Feb; 9(1):32-40. PubMed ID: 18251792
[TBL] [Abstract][Full Text] [Related]
32. Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours.
Schöffski P; Breidenbach I; Krauter J; Bolte O; Stadler M; Ganser A; Wilhelm-Ogunbiyi K; Lentzen H
Eur J Cancer; 2005 Jul; 41(10):1431-8. PubMed ID: 15913988
[TBL] [Abstract][Full Text] [Related]
33. [Value of mistletoe therapy in carcinoma patients].
Rostock M; Unger C
Internist (Berl); 1998 Dec; 39(12):1294-5. PubMed ID: 10198836
[No Abstract] [Full Text] [Related]
34. Long-term administration of galactoside-specific mistletoe lectin in an animal model: no protection against N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats and no induction of a relevant local cellular immune response.
Kunze E; Schulz H; Adamek M; Gabius HJ
J Cancer Res Clin Oncol; 2000 Mar; 126(3):125-38. PubMed ID: 10741906
[TBL] [Abstract][Full Text] [Related]
35. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
36. [Subcutaneous manifestations of a centrocytic non-Hodgkin lymphoma at the injection site of a mistletoe preparation].
Hagenah W; Dörges I; Gafumbegete E; Wagner T
Dtsch Med Wochenschr; 1998 Aug; 123(34-35):1001-4. PubMed ID: 9739765
[TBL] [Abstract][Full Text] [Related]
37. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
38. Disease control, survival, and functional outcome after multimodal treatment for advanced-stage tongue base cancer.
Malone JP; Stephens JA; Grecula JC; Rhoades CA; Ghaheri BA; Schuller DE
Head Neck; 2004 Jul; 26(7):561-72. PubMed ID: 15229898
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract.
Elsässer-Beile U; Leiber C; Wolf P; Lucht M; Mengs U; Wetterauer U
J Urol; 2005 Jul; 174(1):76-9. PubMed ID: 15947582
[TBL] [Abstract][Full Text] [Related]
40. [Mistletoe therapy in cancer treatment: pros and cons].
Wiebelitz KR; Beer AM; Heinrich B
MMW Fortschr Med; 2009 Nov; 151(46):30-1. PubMed ID: 20043390
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
